KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Assets (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Assets for 6 consecutive years, with $527.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets fell 3.97% year-over-year to $527.5 million, compared with a TTM value of $527.5 million through Sep 2025, down 3.97%, and an annual FY2024 reading of $550.6 million, changed 0.47% over the prior year.
  • Assets was $527.5 million for Q3 2025 at Aurinia Pharmaceuticals, up from $502.6 million in the prior quarter.
  • Across five years, Assets topped out at $555.0 million in Q3 2023 and bottomed at $360.1 million in Q3 2021.
  • Average Assets over 5 years is $500.6 million, with a median of $516.6 million recorded in 2024.
  • Peak annual rise in Assets hit 35.61% in 2022, while the deepest fall reached 13.34% in 2022.
  • Year by year, Assets stood at $543.4 million in 2021, then fell by 13.34% to $470.9 million in 2022, then increased by 16.4% to $548.1 million in 2023, then grew by 0.47% to $550.6 million in 2024, then dropped by 4.2% to $527.5 million in 2025.
  • Business Quant data shows Assets for AUPH at $527.5 million in Q3 2025, $502.6 million in Q2 2025, and $504.8 million in Q1 2025.